A carregar...
Akt Inhibitors MK-2206 and Nelfinavir overcome mTOR inhibitor resistance in DLBCL
PURPOSE: The mTOR (mammalian Target of Rapamycin) pathway is constitutively activated in Diffuse Large B-Cell Lymphoma (DLBCL). mTOR inhibitors (mTORi) have activity in DLBCL, although response rates remain low. We evaluated DLBCL cell lines with differential resistance to the mTORi Rapamycin, in or...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3889476/ https://ncbi.nlm.nih.gov/pubmed/22338016 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1407 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|